Patient Registry Study of Berinert® in Normal Clinical Practice

CSL Behring

Status: Completed

Conditions: Includes: Hereditary Angioedema

Treatments: Biological: Berinert® (C1 Esterase Inhibitor)

Study type: Observational

Funder types: Industry

Identifiers

NCT01108848

1500

CE1145_5002

Details and patient eligibility

About

The objective of this patient registry is to collect data on the safety of Berinert® in normal clinical practice in the United States. The patient registry will be maintained for a period of at least 3 years. The duration of individual patient participation will vary and is determined by the frequency of hereditary angioedema (HAE) attacks and the patient's need for Berinert® treatment.

Enrollment: 318 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Any patient receiving CSL Behring's C1-esterase inhibitor
• Written informed consent (may not be required for some retrospective chart review cases)

Exclusion criteria

• Any patient participating in an HAE study using other C1-inhibitors than Berinert®

Trial design

318 participants in 1 patient group

Berinert

Description:

Patients requiring treatment with Berinert®

Treatment:

Biological: Berinert® (C1 Esterase Inhibitor)